NAD+ vs NMN vs NR: Which NAD Booster Actually Works?

Disclaimer: Compounded NAD+ is prepared by a licensed 503A compounding pharmacy and has not been reviewed or approved by the FDA. NMN and NR are sold as dietary supplements. This article reflects my perspective as a pharmaceutical executive and founder. It is not m

Walk down the longevity aisle, physical or digital, and you will find three acronyms competing for your money: NAD+, NMN, and NR. They are marketed as more or less interchangeable, and the marketing is confident to the point of being misleading. As someone who spends a lot of time separating what the evidence supports from what the label claims, I want to give you a grounded comparison, because the differences matter and the honest picture is more nuanced than any supplement ad will tell you.

Start With What They All Have in Common

All three are about one molecule: NAD+, nicotinamide adenine dinucleotide. It is a coenzyme present in every cell, essential for energy metabolism and for the repair enzymes, the sirtuins and PARPs, that maintain cells. NAD+ levels decline with age, and the entire category exists to counteract that decline.[1]

The three products differ in how they try to raise NAD+.

• NAD+ is the molecule itself, delivered directly (by IV or injection in clinical settings).

• NMN (nicotinamide mononucleotide) is a direct precursor, one step away from NAD+.

• NR (nicotinamide riboside) is a precursor one step further back, which the body converts to NMN and then to NAD+.

NMN and NR are the two you see as oral supplements. NAD+ itself is what we provide as an injectable.

What the Science Actually Supports

Here is where I have to be honest in a way the supplement industry usually is not.

The best human evidence is for NR's ability to raise NAD+ when taken orally. In a landmark study, a single oral dose of NR raised blood NAD+ substantially, and the increase was dose-dependent and measurable.[2] That is real, peer-reviewed human data.

NMN also raises NAD+, and there is growing human research, including work showing NMN improved a marker of muscle insulin sensitivity in one clinical population.[3] But here is the honest catch that the marketing omits: despite billions of dollars in combined annual sales, there has never been a head-to-head randomized controlled trial directly comparing NMN and NR on meaningful health outcomes.[4] Anyone telling you definitively that one oral precursor beats the other is going beyond what the evidence can currently support.

So the truthful state of the science is: NR has strong human bioavailability data, NMN has growing data, and no rigorous head-to-head comparison exists to crown a winner. That is less satisfying than a confident marketing claim, but it is accurate.

The Point the Supplement Debate Misses: Delivery

Here is what I think is the more important distinction, and the one the NMN-versus-NR argument largely ignores: how the NAD+ actually gets into your system.

Oral precursors have to survive digestion, be absorbed, and then be converted through one or two metabolic steps into NAD+. That conversion works, but it is indirect, and oral bioavailability is a genuine limitation the research continues to examine.

Injectable NAD+ takes a different route. By delivering NAD+ subcutaneously, you bypass the digestive conversion process entirely and provide the molecule the body is actually trying to raise. For someone whose goal is to raise NAD+ efficiently and consistently, the delivery method is arguably a bigger lever than which oral precursor is theoretically superior.

This is why our program uses injectable NAD+ rather than selling oral precursors. It is not that NMN and NR do nothing; the research says they do raise NAD+. It is that direct delivery sidesteps the bioavailability question that the entire oral-precursor debate is stuck on.

My Honest Take

If you want the truthful bottom line: all three approaches can raise NAD+, NR has the strongest oral bioavailability evidence, NMN has promising and growing data, and no head-to-head trial has settled the oral debate. But the question of oral precursor A versus oral precursor B is, in my view, less important than the question of delivery. Direct injectable NAD+ avoids the conversion and absorption steps that make the oral debate complicated in the first place.

The supplement industry wants you arguing about NMN versus NR because both are products it sells. The more useful question is whether an oral precursor or direct delivery better fits your goal, and that is worth discussing with a provider rather than a supplement label.

To learn how our injectable NAD+ program works, visit our NAD+ therapy page.

References

1. Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529-547. PubMed: 29514064

2. Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948. PubMed: 27721479

3. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed: 34108263

4. Yang Y, et al. An updated review on the mechanisms, pre-clinical and clinical comparisons of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Food Frontiers. 2025. Journal listing

This article reflects my personal perspective as a pharmaceutical executive and founder. It is not medical advice and does not establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. NMN and NR are sold as dietary supplements. Please consult a licensed provider.

JP Rius is the founder of Precision Telemed. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.